Dividend Hike, FDA Updates, and Wall Street’s 2026 Focus
Dec. 12, 2025 — Bristol-Myers Squibb Company (NYSE: BMY ) is back in the spotlight heading into year-end as investors weigh a fresh dividend increase, meaningful regulatory milestones in oncology, and a pipeline that has delivered both high-profile wins and frustrating setbacks in 2025. By mid-day Friday, BMY stock traded around $52.50, up roughly 2.5% , reflecting a market that’s starting to re-price near-term catalysts even as longer-term questions—patent cliffs, trial readouts, and litigation—remain front and center.
BMY stock price today: what’s moving the shares on Dec. 12
The most immediate “today” driver is Wall Street sentiment . On Friday, Guggenheim upgraded Bristol-Myers Squibb to Buy from Neutral and set a $62…
